AI Drug Discovery Push And New Kidney Drug Trial Could Be A Game Changer For China Medical System Holdings (SEHK:867)

Simply Wall St.02-18

In early February 2026, Insilico Medicine announced a partnership with China Medical System Holdings to apply its AI platform to at least two co-developed drug discovery programs, while CMS separately...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612467291?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-02-18 04:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612467291","market":"us","top_or_hot":-1,"title":"AI Drug Discovery Push And New Kidney Drug Trial Could Be A Game Changer For China Medical System Holdings (SEHK:867)","media":"Simply Wall St.","content":"<div>\n<p>In early February 2026, Insilico Medicine announced a partnership with China Medical System Holdings to apply its AI platform to at least two co-developed drug discovery programs, while CMS separately...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/ai-drug-discovery-push-and-new-kidney-drug-trial-could-be-a\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AI Drug Discovery Push And New Kidney Drug Trial Could Be A Game Changer For China Medical System Holdings (SEHK:867)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAI Drug Discovery Push And New Kidney Drug Trial Could Be A Game Changer For China Medical System Holdings (SEHK:867)\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-18 04:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/ai-drug-discovery-push-and-new-kidney-drug-trial-could-be-a><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In early February 2026, Insilico Medicine announced a partnership with China Medical System Holdings to apply its AI platform to at least two co-developed drug discovery programs, while CMS separately...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/ai-drug-discovery-push-and-new-kidney-drug-trial-could-be-a\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4551","symbol_name":"寇图资本持仓","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/ai-drug-discovery-push-and-new-kidney-drug-trial-could-be-a","article_id":"2612467291","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-867/china-medical-system-holdings-shares/news/ai-drug-discovery-push-and-new-kidney-drug-trial-could-be-a","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2612467291","pubTimestamp":1771359400,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"In early February 2026, Insilico Medicine announced a partnership with China Medical System Holdings to apply its AI platform to at least two co-developed drug discovery programs, while CMS separately received Chinese regulatory approval to begin human clinical trials of its self-developed complement factor B inhibitor CMS-D017 for complement-mediated kidney diseases.\nTogether, the AI-enabled collaboration and first-in-human trial clearance highlight CMS’s push to build an innovative...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4551":"寇图资本持仓","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","BK1191":"制药","IE00BYV24P56.USD":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","00867":"康哲药业","BK1593":"医美概念股","BK4023":"应用软件","IE00BMCWC346.EUR":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC","BK4543":"AI","AI":"C3.ai, Inc.","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4587":"ChatGPT概念","IE00BVYPNQ40.USD":"GUINNESS ASIAN EQUITY INCOME \"C\" (USD) ACC","BK4528":"SaaS概念","SG9999015978.USD":"利安颠覆性创新基金A","IE00BGHQDM52.EUR":"GUINNESS ASIAN EQUITY INCOME \"C\" (EUR) ACC","IE00BVYPNP33.GBP":"GUINNESS ASIAN EQUITY INCOME \"C\" (GBP) ACC","BK4588":"碎股","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD"},"translate_title":"人工智能药物发现推动和新型肾脏药物试验可能会改变康哲药业（SEHK：867）的游戏规则","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AI":0.9,"00867":0.9},"content_text":"In early February 2026, Insilico Medicine announced a partnership with China Medical System Holdings to apply its AI platform to at least two co-developed drug discovery programs, while CMS separately received Chinese regulatory approval to begin human clinical trials of its self-developed complement factor B inhibitor CMS-D017 for complement-mediated kidney diseases. Together, the AI-enabled collaboration and first-in-human trial clearance highlight CMS’s push to build an innovative pipeline in nephrology and immune-related conditions alongside its existing commercial portfolio. We’ll now examine how CMS’s move into AI-powered discovery and complement factor B inhibition shapes the company’s broader investment narrative. Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.AdvertisementWhat Is China Medical System Holdings' Investment Narrative?To own China Medical System, you need to believe that its mix of established commercial drugs and a growing roster of innovative assets can justify a premium P/E and a share price already up strongly over the past year. Before the February 2026 updates, the near term story leaned heavily on NDAs like Y-3, ruxolitinib cream and ZUNVEYL, plus steady earnings growth and buybacks. The Insilico partnership and CMS-D017’s first-in-human clearance add early stage, higher risk optionality in nephrology and immune disease, but they are unlikely to be major earnings drivers in the short run. Instead, they slightly tilt the catalyst set toward clinical and data readouts, while also raising execution and R&D spend risk around an innovation push that still needs to prove itself. However, this innovation tilt also introduces a new layer of R&D and execution risk that investors should know about.\nChina Medical System Holdings' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.Exploring Other PerspectivesSEHK:867 1-Year Stock Price Chart Two fair value estimates from the Simply Wall St Community span roughly HK$17.20 to HK$34.05, showing how differently private investors are valuing CMS’s prospects. Set against CMS’s push into AI discovery and complement inhibition, that spread underlines how much depends on clinical progress and execution in the newer pipeline.Explore 2 other fair value estimates on China Medical System Holdings - why the stock might be worth over 2x more than the current price!The Verdict Is YoursDon't just follow the ticker - dig into the data and build a conviction that's truly your own.A great starting point for your China Medical System Holdings research is our analysis highlighting 3 key rewards that could impact your investment decision.Our free China Medical System Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate China Medical System Holdings' overall financial health at a glance.Ready To Venture Into Other Investment Styles?Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 26 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612467291","isCrawlerRequest":true}